<italic toggle="yes">In Vivo</italic> Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix

ABSTRACT Protease inhibitors (PIs) are the second- and last-line therapy for the majority of HIV-infected patients worldwide. Only around 20% of individuals who fail PI regimens develop major resistance mutations in protease. We sought to explore the role of mutations in gag-pro genotypic and phenot...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rawlings Datir, Steven Kemp, Kate El Bouzidi, Petra Mlchocova, Richard Goldstein, Judy Breuer, Greg J. Towers, Clare Jolly, Miguel E. Quiñones-Mateu, Patrick S. Dakum, Nicaise Ndembi, Ravindra K. Gupta
Formato: article
Lenguaje:EN
Publicado: American Society for Microbiology 2020
Materias:
HIV
Acceso en línea:https://doaj.org/article/7199b87aeca649fba51303efebde939d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!